Shared copy number variation in simultaneous nephroblastoma and neuroblastoma due to Fanconi anemia

Molecular Syndromology

Volumn 3, Issue 3, 2012, Pages 120-130

  Serra, A ^a   Eirich, K ^b   Winkler, A K ^a   Mrasek, K ^c   Ghring, G ^d   Barbi, G ^a   Cario, H ^a   Schlegelberger, B ^d   Pokora, B ^e   Liehr, T ^c   Leriche, C ^a   Henne Bruns, D ^a   Barth, T F ^a   Schindler, D ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Copy number variation; Fanconi anemia; Nephroblastoma; Neuroblastoma; PALB2 mutation

Indexed keywords

DACTINOMYCIN; PALB2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER STEM CELL; CASE REPORT; CHROMOSOMAL INSTABILITY; CHROMOSOME 11P; CHROMOSOME 17Q; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; FANCONI ANEMIA; FEMALE; FIBROBLAST CULTURE; FRAMESHIFT MUTATION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRACRANIAL HYPERTENSION; LYMPHADENECTOMY; MEDULLOBLASTOMA; MORTALITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHRECTOMY; NEPHROBLASTOMA; NEUROBLASTOMA; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL LYMPHOCYTE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL;

EID: 84866537310     PISSN: 16618769     EISSN: 16618777     Source Type: Journal    
DOI: 10.1159/000341935     Document Type: Article

References (48)

1. Abbondanzo SL, Manz HJ, Klappenbach RS, Gootenberg JE: Hepatocellular carcinoma in an 11-year-old girl with Fanconi's anaemia. Report of a case and review of the literature. Am J Pediatr Hematol Oncol 8:334-337 (1986).
2. Alter BP: Cancer in Fanconi anemia, 1927-2001. Cancer 97:425-440 (2003).
3. Ambros PF, Ambros IM: SIOP Europe Neuro-blastoma Pathology, Biology, and Bone Marrow Group. Pathology and biology guidelines for resectable and unresectable neuro-blastic tumors and bone marrow examination guidelines. Med Pediatr Oncol 37:492-504 (2001)
4. Astuti D, Latif F, Wagner K, Gentle D, Cooper WN, et al: Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neopla-sia: analysis of neuroblastoma, phaeochro-mocytoma and Wilms' tumour. Br J Cancer 92:1574-1580 (2005).
5. Barth TF, Benner A, Bentz M, Döhner H, Möller P, Lichter P: Risk of false positive results in comparative genomic hybridization. Genes Chromosomes Cancer 28:353-357 (2000).
6. Berger A, Tuechler C, Almer D, Kogner P, Ratschek M, et al: Elevated expression of galanin receptors in childhood neuroblastic tumors. Neuroendocrinology 75:130-138 (2002).
7. Berrebi D, Lebras MN, Belarbi N, Couturier J, Fattet S, et al: Bilateral adrenal neuroblasto-ma and nephroblastoma occurring synchronously in a child with Fanconi's anaemia and VACTER-L syndrome. J Pediatr Surg 41:e11-14 (2006).
8. Bissig H, Staehlin F, Tolnay M, Avoledo P, Richter J, et al: Co-occurrence of neuroblastoma and nephroblastoma in an infant with Fan-coni's anaemia. Hum Pathol 33:1047-1051 (2002).
9. Chung B, Shaffer LG: From VACTER-L to het-erotaxy: variable expressivity of ZIC3-relat-ed disorders. Am J Med Genet 155:1123-1128 (2011).
10. Compostella A, Toffolutti T, Soloni P, Dall'Igna P, Carli M, Bisogno G: Multiple synchronous tumors in a child with Fanconi anaemia. J Pediatr Surg 45:e5-8 (2010).
11. Damian MS, Seibel P, Schachenmayr W, Reichmann H, Dorndorf W: VACTER-L with the mitochondrial NP 3243 point mutation. Am J Med Genet 62:398-403 (1996).
12. de Chadarévian JP, Vekemans M, Bernstein M: Fanconi's anaemia, medulloblastoma, Wilms' tumor, horseshoe kidney, and go-nadal dysgenesis. Arch Pathol Lab Med 109:367-369 (1985).
13. DeWire MD, Ellison DW, Patay Z, McKinnon PJ, Sanders RP, Gajjar A: Fanconi anaemia and biallelic BRCA2 mutation diagnosed in a young child with an embryonal CNS tumor. Pediatr Blood Cancer 53:1140-1142 (2009).
14. Eckerle I, Muth D, Batzler J, Henrich KO, Lutz W, et al: Regulation of BIRC5 and its isoform BIRC5-2B in neuroblastoma. Cancer Lett 285:99-107 (2009).
15. Faivre L, Portnoi MF, Pals G, Stoppa-Lyonnet D, Le Merrer M, et al: Should chromosome breakage studies be performed in patients with VACTERL association. Am J Med Genetics 137A:55-58 (2005).
16. Garcia-Barcelo MM, Wong KK, Lui VC, Yuan Z, So M, et al: Identification of a HOX D13 mutation in a VACTER-L patient. Am J Med Genet 146A:3181-3185 (2008).
17. Göhring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA: Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood 116:3766-3769 (2010).
18. Hirsch B, Shimamura A, Moreau L, Baldinger S, Hagalshiekh M, et al: Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood 103:2554-2559 (2004).
19. Hubertus J, Lacher M, Rottenkolber M, MüllerHöcker J, Berger M, et al: Altered expression of imprinted genes in Wilms tumors. Oncol Rep 25:817-823 (2011).
20. ISCN (2009): An International System for Human Cytogenetic Nomenclature, Shaffer L, Slovak M, Campbell L (eds) (S.Karger Verlag, Basel 2009).
21. Karnik P, Chen P, Paris M, Yeger H, Williams BR: Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions. Oncogene 17:237-240 (1998).
22. Katoh Y, Katoh M: Identification and characterization of DISP3 gene in silico. Int J Oncol 26:551-556 (2005).
23. Katyal S, Glubrecht DD, Li L, Gao Z, Godbout R: Disabled-1 alternative splicing in human fetal retina and neural tumors. PLoS One 6:e28579 (2011).
24. Kim JH, Kim PC, Hui C: The VACTER-L association: lessons from the Sonic hedgehog pathway. Clin Genet 59:306-315 (2001).
25. Kopic S, Eirich K, Schuster B, Hanenberg H, Va-ron-Mateeva R, et al: Hepatoblastoma in a 4-year-old girl with Fanconi anaemia. Acta Paediatr 100:780-783 (2011).
26. Kusafuka T, Naga hara N, Oue T, Imura K, Na ka-mura T, et al: Unfavorable DNA ploidy and Ha-ras p21 findings in neuroblastomas detected through mass screening. Cancer 76:695-699 (1995).
27. Lava rino C, Cheung NK, G a rcia I, Domenech G, de Torres C, et al: Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuro-blastoma BMC Cancer 9: 44 (2009).
28. Leone A, Seeger RC, Hong CM, Hu YY, Arboleda MJ, et al: Evidence for nm23 RNA overex-pression, DNA amplification and mutation in aggressive childhood neuroblastomas. Oncogene 8:855-865 (1993).
29. Mai M, Qian C, Yokomizo A, Smith DI, Liu W: Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24. Genomics 55:341-344 (1999).
30. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215 (1988).
31. Neveling K, Endt D, Hoehn H, Schindler D: Gen-otype-phenotype correlations in Fanconi anemia. Mut Res 668:73-91 (2009).
32. Niu GM, Ji Y, Jin DY, Hou J, Lou WH: Clinical implication of BRSK2 expression in pancreatic ductal adenocarcinoma. Zhonghua Yi Xue Za Zhi 90:1084-1088 (2010).
33. Perel Y, Butenandt O, Carrere A, Saura R, Lamireau T, Vergnes P: Oesophageal atresia, VACTERL association: Fanconi's anaemia related spectrum of anomalies. Arch Dis Child 78:375-376 (1998).
34. Quan L, Smith DW: The VATER association: vertebral defects, analatresia, tracheoes oph-ageal fistula with esophageal atresia, radial dysplasia. Birth Defects Orig Art Ser VIII:75-78 (1972).
35. Raghunath M, Patti R, Bannerman P, Lee CM, Baker S, et al: A novel kinase, AATYK induces and promotes neuronal differentiation in a human neuroblastoma (SH-SY5Y) cell line. Brain Res Mol Brain Res 77:151-162 (2000).
36. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, et al: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39:162-164 (2007).
37. Royer-Pokora B: Genetische Prädisposition für Wilms-Tumor. Medgen 19:234-238 (2007).
38. Royer-Pokora B, Busch M, Beier M, Duhme C, de Torres C, et al: Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Hum Mol Genet 19:1651-1668 (2010).
39. Sagulenko V, Muth D, Sagulenko E, Paffhausen T, Schwab M, Westermann F: Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcino-genesis 29:1869-1877 (2008).
40. Sari N, Akyuz C, Aktas D, Gumruk F, Orhan D, et al: Wilms tumor, AML and medulloblas-toma in a child with cancer prone syndrome of total premature chromatid separation and Fanconi anaemia. Pediatr Blood Cancer 53:208-210 (2009).
41. Schlegelberger B, Metzke S, Harder S, Zhang Y, Siebert R: Classical and molecular cytoge-netics of tumor cells, in Wegener R (ed): Diagnostic Cytogenetics, pp 151-185 (Springer Verlag, Heidelberg 1999.)
42. SIOP-2001/GPOH: Phase III partially-randomized study of neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in children with Wilms' tumor. Nephro-blastoma (Wilms Tumour) Clinical Trial and Study, Register NCT00047138, Start date 12.01.2001.
43. Sköldenberg EG, Larsson A, Jakobson A, Hedborg F, Kogner P, et al: The angiogenic growth factors HGF and VEGF in serum and plasma from neuroblastoma patients. Anticancer Res 29:3311-3319 (2009).
44. Stone DL, Biesecker LG: Mitochondrial NP 3243 point mutation is not a common cause of VACTER-L association. Am J Med Genet 72:237-238 (1997).
45. Van Zeeburg HJ, Snijders PJ, Wu T, Gluckman E, Soulier J, et al: Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anaemia patients. J Natl Cancer Inst 100:1649-1653 (2008).
46. Vu TH, Chuyen NV, Li T, Hoffman AR: Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res 63:1900-1905 (2003).
47. Wang C, Liu Z, Woo CW, Li Z, Wang L, et al: EZH2 mediates epigenetic silencing of neuroblasto-ma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res 72:315-324 (2012).
48. Zen PR, Riegel M, Rosa RF, Pinto LL, Graziadio C, et al: Esophageal stenosis in a child presenting a de novo 7q terminal deletion. Eur J Med Genet 53:333-336 (2010).